Impact of 18F-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP

Nuclear Medicine and Biology

Volumn 40, Issue 4, 2013, Pages 518-523

  Storto, Giovanni ^a   Gallicchio, Rosj ^a   Pellegrino, Teresa ^b   Nardelli, Anna ^b   De Luca, Serena ^b   Capacchione, Daniela ^a   Sirignano, Cesare ^b   Pace, Leonardo ^c  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

18F fluoride PET CT; Bone scan; Early bone pain; Radionuclide therapy; Sm 153 EDTMP

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CONTRAST MEDIUM; ETIDRONIC ACID TC 99M; FLUORINE 18; LEXIDRONAM SAMARIUM SM 153; NONSTEROID ANTIINFLAMMATORY AGENT; ZOLEDRONIC ACID; FLUORIDE; FLUORINE; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE; DIAGNOSTIC AGENT;

ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; EARLY INTERVENTION; HUMAN; MALE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE; AGED; BONE TUMOR; COMPLICATION; MULTIMODAL IMAGING; PAIN; PAIN MEASUREMENT; PALLIATIVE THERAPY; PATHOLOGY; PROSTATE TUMOR; SCINTISCANNING; SECONDARY; TIME FACTOR; METASTASIS; PAIN ASSESSMENT; TIME;

AGED; BONE NEOPLASMS; FLUORIDES; FLUORINE RADIOISOTOPES; HUMANS; MALE; MULTIMODAL IMAGING; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 84876730691     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.02.009     Document Type: Article

References (38)

1. Resche I., Chatal J.F., Pecking A., et al. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997, 33:1583-1591.
2. Sartor O., Reid R.H., Hoskin P.J., et al. Quadramet 424Sm10/11 Study Group. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004, 63:940-945.
3. Serafini A.N. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastasis. Cancer 2000, 88:2934-2939.
4. Serafini A.N., Houston S.J., Resche I., et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998, 16:1574-1581.
5. Ricci S., Boni G., Pastina I., et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2007, 34:1023-1030.
6. Sciuto R., Festa A., Rea S., et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002, 43:79-86.
7. Storto G., Klain M., Paone G., et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 2006, 39:35-41.
8. Thrall J.H. Technetium-99m labeled agents for skeletal imaging. CRC Crit Rev Clin Radiol Nucl Med 1976, 8:1-31.
9. Davis M.A., Jones A.G. Comparison of 99mTc-labeled phosphate and phosphonate agents for skeletal imaging. Semin Nucl Med 1976, 6:19-31.
10. Hawkins R.A., Choi Y., Huang S.C., et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 1992, 33:633-642.
11. Hoh C.K., Hawkins R.A., Dahlbom M., et al. Whole body skeletal imaging with [18F]fluoride ion and PET. J Comput Assist Tomogr 1993, 17:34-41.
12. Schirrmeister H., Guhlmann A., Elsner K., et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999, 40:1623-1629.
13. Schirrmeister H., Guhlmann A., Kotzerke J., et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999, 17:2381-2389.
14. Tse N., Hoh C., Hawkins R., Phelps M., Glaspy J. Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma. Am J Clin Oncol 1994, 17:22-25.
15. Collins C., Eary J.F., Donaldson G., et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993, 34:1839-1844.
16. Pandit-Taskar N., Batraki M., Divgi C.R. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004, 45:1358-1365.
17. Keller E.T., Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biol 2004, 91:718-729.
18. Ribiero M., Ruff P., Falkson G. Low serum testosterone and a younger age predict poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997, 20:605-608.
19. Auclerc G., Antoine E.C., Cajfinger F., Brunet-Pommeyrol A., Agazia C., Khayat D. Management of advanced prostate cancer. Oncologist 2000, 5:36-44.
20. Reich C.D. Advances in the treatment of bone metastases. Clin J Oncol Nurs 2003, 7:641-646.
21. Coronado M., Redondo A., Coya J., et al. Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease. Clin Nucl Med 2006, 31:605-610.
22. Serafini A.N. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q J Nucl Med 2001, 45:91-99.
23. Lewington V.J. Bone-seeking radionuclides for therapy. J Nucl Med 2005, 46:38S-47S.
24. Turner J.H., Claringbold P.G. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991, 27:1085-1086.
25. Porter A.T., McEwan A.J., Powe J.E., et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993, 25:805-813.
26. Quilty P.M., Kirk D., Bolger J.J., et al. A comparison of the effects of strontium-89 and external beam radiotherapy in metastatic prostatic carcinoma. Radiother Oncol 1994, 31:33-40.
27. Iagaru A., Mittra E., Yaghoubi S.S., et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med 2009, 50:501-505.
28. Hetzel M., Arslandemir C., König H.H., et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 2003, 18:2206-2214.
29. Langsteger W., Heinisch M., Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006, 36:73-92.
30. Yen R.F., Chen C.Y., Cheng M.F., et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun 2010, 31:637-645.
31. Even-Sapir E., Metser U., Mishani E., Lievshitz G., Lerman H., Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18Ffluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006, 47:287-297.
32. 18F-fluoride PET/CT. J Nucl Med 2004, 45:272-278.
33. Petren-Mallmin M., Andreasson I., Ljunggren O., et al. Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol 1998, 27:72-76.
34. Grant F.D., Fahey F.H., Packard A.B., Davis R.T., Alavi A., Treves S.T. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008, 49:68-78.
35. Park-Holohan S.J., Blake G.M., Fogelman I. Quantitative studies of bone using 18Ffluoride and 99mTc-methylene diphosphonate: evaluation of renal and whole blood kinetics. Nucl Med Commun 2001, 22:1037-1044.
36. Kawaguchi M., Tateishi U., Shizukuishi K., Suzuki A., Inoue T. 18F-fluoride uptake in bone metastasis: morphologic and metabolic analysis on integrated PET/CT. Ann Nucl Med 2010, 24:241-247.
37. Beheshti M., Vali R., Waldenberger P., et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008, 35:1766-1774.
38. Lewington V.J. Cancer therapy using bone-seeking isotopes. Phys Med Biol 1996, 41:2027-2042.